Liquid biopsies have emerged as a groundbreaking approach in cancer diagnostics, enabling the detection of DNA shed by cancer cells through a simple blood test. However, cancer cells also shed RNA into the blood.
Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.
Stanford scientists have discovered that differentially methylated regions (DMRs) in circulating tumor DNA (ctDNA) can be used as a blood-based biomarker for early cancer detection.
Stanford researches have formulated a robust database called PRECOG (Prediction of Clinical Outcomes from Genomics) that connects cancer genome expression and patient survival/outcomes in a more predictive and extensive collection than any other signature on the market.